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merging Paradigms,
latforms, and Unifying
hemes in Biomarker Science*
ichard C. Becker, MD
urham, North Carolina
Since the object of pure scientific knowledge cannot be other than
it is, the truth obtained by demonstrative knowledge will be
necessary.
Aristotle, Analytica Posteriora (1)
he relationship between platelets, leukocytes, and the
ndothelium highlights a complex balance between normal
iology and pathobiology, adaptation and maladaption,
ealth, and disease. Although it is increasingly apparent that
nflammation is a unifying theme for trauma, environmental
See page 1768
oxins, and a highly evolved immune system that quickly
ecognizes and responds to nonself inhabitants and intruders, it
s equally apparent that inflammation is in many instances
ecessary, but not sufficient to explain common clinical
henotypes in cardiovascular disease.
iomarkers: A Traditional Paradigm
iomarkers are measurable cells, proteins, and/or metabolic
yproducts that represent, either directly or indirectly, one or
ore processes in a defined biological system or disease
tate (2). Because biomarkers reflect health and disease
ccording to genetic makeup, gene–gene interactions, gene–
nvironmental interactions, and a dynamic interface be-
ween genotype–phenotype relationships (3), one could
onsider biomarkers in categories of antecedent biomarkers
identifying the inherent or existing risk of developing a
isease), screening biomarkers (a screening tool for subclin-
cal disease), diagnostic biomarkers (recognition of existing
isease), staging biomarkers (categorizing the severity of
isease), and prognostic biomarkers (predicting the natural
istory of disease, including response to treatment and
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Duke University School of Medicine, Duke Cardiovascular Thrombosis
enter, Duke Clinical Research Institute, Durham, North Carolina. Dr. Beckera
eceives research support from Regado Biosciences, Momena Pharmaceutcials,
straZeneca, and Bristol-Myers Squibb.ikelihood of adverse effects related to treatment) (reviewed
y Vasan [4]). A category that to date has eluded cardio-
ascular medicine is target biomarkers (altering the pheno-
ype through specific treatment aimed at the biomarker
tself or a functional byproduct).
In this issue of the Journal, Cavusoglu et al. (5) report an
ssociation between plasma F11 receptor/junctional adhe-
ion molecule (F11R/JAM-A) levels and human atheroscle-
osis. In a cohort of 389 male patients undergoing coronary
ngiography, F11R was shown to correlate with the pres-
nce and severity of obstructive disease according to a
alidated risk score. By multivariate analysis that included
igh-sensitivity C-reactive protein, plasminogen activator
nhibitor-1, matrix metalloproteinase-9, tissue inhibitor of
etalloproteinase-1, insulin, and tumor necrosis factor al-
ha, F11R was the only measured biomarker that was
ndependently associated with coronary artery disease score.
he investigators conclude “strategies that block F11R may
epresent a novel approach to the treatment of human
therosclerosis.”
iomarkers of Atherosclerotic
laque and Prevalent Clinical Phenotypes
he relationship between inflammation and atheroscle-
osis is well established, with a wide variety of molecules
eing represented in varying stages of disease, includ-
ng T-lymphocytes, monocyte-derived macrophages, and
ttendant-mediator proteins such as growth factors, cy-
okines, chemokines, proteolytic enzymes, and disinte-
rins (reviewed by Koenig and Khuseyinova [6]). More
han 30 cohort and nested case-control studies have been
eported for C-reactive protein alone as a prognostic
iomarker for future cardiovascular events (reviewed by
rmstrong et al. [7]). The experience to date clarifies the
eed for integrated pathways of investigation.
pplied Vascular Biology
ost cells, including those of the vascular endothelium,
ommunicate with their adjacent neighboring cells via tight
unctions. The junction or gap itself is spanned by connect-
ng channels known as connexons that permit water-soluble
olecules and inorganic ions to pass directly from the
ytoplasm of one cell to the cytoplasm of another, coupling
he cells both metabolically and electrically. Under normal
ircumstances, the functional pore size of a tight junction is
.5 nm; thus, macromolecules such as proteins, polysaccha-
ides, and nucleic acids would not be shared between cells.
Individual tight junctions are in a state of dynamic flux,
pening and closing in response to local cellular conditions
nd extracellular signals. Based on structural and functional
roperties, 3 types of integral membrane proteins are rec-
gnized. The first type, containing 4 transmembrane do-
ains that are responsible for establishing a structural basis
or barrier and gate functions, includes tricellulin, claudin,
nd occludin (8). The second type, represented by Crumbs
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Editorial Comment October 30, 2007:1777–803 complex, is important for normal cellular polarity for-
ation. The third type comprises members of the immu-
oglobulin superfamily and includes JAM-A (the protein of
ocus for the current study), Coxsackie-and-Adenovirus
eceptor (CAR), JAM-4, CAR-like membrane protein,
nd endothelial-cell selective adhesion molecule (9). Al-
hough the functional roles for this particular group of
roteins have not been determined fully, the available
vidence points toward their importance as landmarks for
unctional localization of cell polarity proteins to sites of
ell–cell adhesion.
hat is the Likelihood That F11R/JAM-A
nhibition Can Either Prevent or Change the Natural
istory of Atherothrombotic Vascular Disease?
avusoglu et al. (5), based on observations from a cohort of
89 male patients with varying degrees of obstructive
oronary artery disease, conclude that “strategies designed to
lock F11R-mediated adhesion of platelets to endothelial
ells may represent a novel approach to the prevention and
reatment of human atherosclerosis.” Although identifica-
ion of a circulating biomarker that is associated with an
ntermediate phenotype does not establish mechanistic cau-
ality, and in turn, an expected benefit derived from its
ttenuation or complete inhibition, the investigators’ hy-
othesis is biologically plausible.
F11R/JAM-A, a transmembrane protein expressed at
ight junctions of endothelial cells and on the surface of
latelets and leukocytes, is known to participate in leukocyte
iapedesis (reviewed by Nourshargh et al. [10]). In addition,
umor necrosis factor alpha, a proinflammatory cytokine,
rovokes changes in endothelial cell morphology and per-
eability through reorganizing of tight junction proteins,
ncluding JAM-A and occludin (11). The role of JAM-A in
eukocyte transmigration in vivo has been observed directly
y intravital microscopy using JAM-A neutralizing mono-
lonal antibody (BV11) and in JAM-A deficient (KO) mice
12). Although leukocyte transmigration was reduced in
oth wild-type mice treated with BV11 and in JAM-KO
ice after stimulation with interleukin-1 beta or ischemia-
eperfusion injury, neither had an effect on responses elicited
y LTB4 or platelet activating factor. In vivo data generated
ith blocking antibodies or through inactivation of the
AM-A gene suggest that its contribution to leukocyte
ecruitment is highly dependent on local conditions (re-
iewed by Nourshargh et al. [10]). Soluble forms of JAM-A
c have been shown to reduce stromal cell-derived factor-1
lpha-triggered transendothelial chemotaxis of activated T
ells and their arrest on cytokine-costimulated endothelium
nder flow conditions (13).
The oxidized low-density lipoprotein up-regulation of
ytokine-stimulated expression of endothelial cell and
acrophage JAM-A/F11R is a particularly important
unctional construct that warrants consideration in future
tudies. ws There a Risk for Vascular
oxicity With JAM-A Inhibition?
ertebrate epithelial cells are characterized by apico-basal
olarity with a free apical domain and a bounded basolateral
embrane domain that is in contact with either neighbor-
ng cells or the extracellular matrix (reviewed by Rehder
t al. [14]). Tight junctions restrict the free diffusion of
ntramembrane proteins between the apical and basolateral
embrane domains and, as a result, are required to maintain
hysiological apico-basal polarity.
Studies with JAM-A mutants lacking the V-type immu-
oglobulin domain suggest that it is critical for the devel-
pment of normal cellular morphology (15). Similarly, in
rosophila epithelial cells, JAMsi RNA suppresses cyst
ormation-spherical structures with a central lumen lined by
monolayer of highly polarized cells. Cyst formation is vital
or coordinated cell behavior, and their ability to establish
istinct membrane domains (16). JAM-A–deficient murine
ndothelial cells, when exposed to shear stress, display
ncreased protrusion extension in the direction of flow and
ecreased upstream displacement (17). Thus, JAM-A pro-
ein may be a critical developmental component of cellular
tructure and function, and even when overexpressed in
onditions characterized by cytokine-mediated endothelial
ell and/or platelet activation, still plays an essential role in
ormal vascular biology. Whether short-term inhibition or
ore prolonged attenuation of JAM-A could be achieved
ithout incurring a “price of vascular toxicity” will require
urther preclinical investigation.
latforms for Biomarkers in Cardiovascular Disease
onceptually, biomarkers of interest should be based on the
iology of health and disease, with an established link to the
henotype under investigation and tested in several relevant
odel systems. The investigative group responsible for the
urrent work (5) followed a highly laudable and exemplary
ath. They identified, sequenced, and cloned the human
ene for F11R/JAM-A (18), and subsequently demon-
trated high levels of F11R/JAM-A mRNA and F11R/
AM-A protein within atherosclerotic plaques derived from
atients with aortic peripheral vascular disease (19). The
ndings were reproduced in atherosclerosis-prone apoli-
oprotein E/ mice (19). Finally, they developed an
11R/JAM-A enzyme-linked immunoadsorbent assay, and
erein report, for the first time, the detection, quantifica-
ion, and characterization of F11R/JAM-A in the plasma of
atients with atherosclerotic coronary artery disease. The
nvestigators have established a platform for future studies
hat will provide a basis for answering several important
uestions such as: What is the site(s) of origin for soluble
11R protein, and how does this influence functionality?
oes the lower soluble F11R concentration among individ-
als with myocardial infarction represent a change in pro-
ein conformation and/or condition-modified molecules
ith altered biological activity? Last, is the relationship
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October 30, 2007:1777–80 Editorial Commentetween coronary artery occlusive disease and F11R similar
r different among women compared with men?
.S. Food and Drug Administration
osition on Biomarkers
he U.S. Food and Drug Administration has a long-
tanding interest in biomarkers. Several recent examples in
hich advanced biomarkers might have been particularly
seful for detecting early signals of vascular toxicity and/or
rug-induced prothrombotic effects include cyclooxy-
enase-2 inhibitors (20), torcetrapib (21), and rosiglitazone
22).
ational Institutes of Health
osition on Biomarkers
he National Institutes of Health, in multiple forums (4),
as made their position on biomarkers clear. They view
enomics, proteomics, metabolomics, and combinatorial
hemistry (as well as high-throughput technologies) as
epresenting a means to relieve an existing bottleneck in
rug discovery, improve the efficiency of clinical trials, speed
he translation of basic science to the bedside, and address
merging public health issues.
iomarkers: A Contemporary Paradigm
contemporary view of biomarkers builds on a strong
oundation provided by early observations and introduces 2
undamental, translatable constructs: (1) platforms for sci-
ntific discovery and integration of large complex datasets
hrough bioinformatics, and (2) technology-based and
ystems-based approaches for probing mechanisms of dis-
ase and establishing overarching themes for advanced
tudy.
Accordingly, the scientific community must embark on a
ontemporary approach, using emerging molecular, cellular,
Figure 1 Systems Biology Creates a Human Biosignature
An ability to understand human health and disease, cell-based and advanced
biomarkers, and both safe and effective pharmacotherapies requires an inte-
grated approach to investigation. DNA  deoxyribonucleic acid; MRNA  mes-
senger ribonucleic acid.rotein-chemistry, metabolic, and tissue imaging platforms
23) (Fig. 1).
esting a Hypothesis
he 5 phases of biomarker development outlined by Pepe
t al. (24), with recent modifications by Vasan (4), warrants
onsideration and is relevant to the potential use of F11R/
AM-A as a marker of atherothrombotic coronary artery
isease. The journey to phase 5 requires commitment,
ision, and resources, particularly when a biomarker is
ltimately selected as a target for intervention.
The cardiology community must acknowledge that it is
0 years behind our oncology colleagues who have, several
imes over, connected the operative dots of genotype–
henotype treatment, tying them together with a golden
hread of molecular and protein biomarkers to distinguish
he presence of disease, establish a prognosis, apply specific
herapy, and predict treatment response. There have been
dvances within cardiology (25,26) and translatable road
aps for success (27,28), but progress remains wanting.
Cavusoglu et al. (5) have introduced a new piece to the
uzzle that defines atherothrombotic coronary artery dis-
ase. One must applaud their attention to scientific rigor
nd commitment to the tenet of translatability. Will F11R/
AM-A emerge as a biomarker worthy of favored status, and
ith it, an opportunity to be fully characterized for its merit,
r will it be sentenced to a life of obscurity and isolation
long with scores of other biomarkers? The answer to the
uestion lies in the hands, minds, and imagination of those
ho have grown weary of hearing year after year “cardio-
ascular disease is the leading cause of death among men
nd women in the United States and developing world.”
eprint requests and correspondence: Dr. Richard C. Becker,
ardiovascular Thrombosis Center, Duke Clinical Research Insti-
ute, 2400 Pratt Street, Durham, North Carolina 27705. E-mail:
ecke021@mc.duke.edu.
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